Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many core safety/management concepts (immune-mediated adverse reactions, organ-specific immune toxicities, severity-based withholding/discontinuation, corticosteroid-based management, and infectious workup consideration in steroid-refractory colitis) are supported by the label. However, numerous extracted claims are unsupported or over-specific (e.g., “immune-toxicity playbook,” infliximab use as a specific option for steroid-refractory colitis, pneumonitis workup details like imaging/oxygen, detailed patient-warning wording, and mechanistic rationale phrased as “dampen the immune response driving toxicity”), and several claims are framed as typical without label support.
Category Scores
Accurate Statements
Yervoy can trigger immune-mediated adverse reactions that may be severe or fatal and can occur in any organ system or tissue.
5.1 Severe and Fatal Immune-Mediated Adverse Reactions
Yervoy can cause immune-mediated pneumonitis (lung).
5.1 Immune-Mediated Pneumonitis
Yervoy can cause immune-mediated colitis (colon).
5.1 Immune-Mediated Colitis
Yervoy can cause immune-mediated hepatitis (liver).
5.1 Immune-Mediated Hepatitis
Yervoy can cause immune-mediated dermatologic reactions, including severe rash presentations (e.g., bullous/exfoliative dermatitis, SJS/TEN, DRESS).
5.1 Immune-Mediated Dermatologic Adverse Reactions
Yervoy can cause immune-mediated nephritis with renal dysfunction (kidneys).
5.1 Immune-Mediated Nephritis with Renal Dysfunction
Management involves withholding or permanently discontinuing Yervoy depending on severity/grade, with Grade 3 generally withhold and Grade 4 life-threatening generally permanently discontinue.
2.3; 5.1 Withhold or permanently discontinue depending on severity
Management includes initiating systemic corticosteroid therapy and tapering after improvement to Grade 1 or less.
5.1: administer systemic corticosteroid therapy until improvement to Grade 1 or less; initiate corticosteroid taper
If immune-mediated adverse reactions are not controlled with corticosteroids, consider other systemic immunosuppressants.
5.1: Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy
In steroid-refractory immune-mediated colitis, consider repeating infectious workup to exclude alternative etiologies.
5.1 Immune-Mediated Colitis: In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies
For pneumonitis, systemic corticosteroids were required and pneumonitis management is grade-based (e.g., Grade 2 withhold; Grade 3/4 permanently discontinue).
5.1 Immune-Mediated Pneumonitis; 2.3 Table 3 Pneumonitis
Unsupported Statements
Immune-related reactions from Yervoy are treated as immune-mediated until proven otherwise.
Label provided does not contain this specific 'until proven otherwise' treatment framing.
Management of Yervoy immune-related side effects typically follows an immune-toxicity playbook.
No 'playbook' concept is stated in the provided label text.
In certain cases of immune colitis that are steroid-refractory, infliximab may be used for Yervoy immune-related side effects.
The provided label excerpt mentions considering other systemic immunosuppressants and infectious workup for steroid-refractory colitis, but does not name infliximab for immune colitis.
Patients with suspected Yervoy pneumonitis are typically monitored closely for breathing symptoms such as shortness of breath and new or worsening cough.
The provided label excerpt does not specify this monitoring approach for pneumonitis symptoms.
For Yervoy pneumonitis, clinicians evaluate with imaging and assess oxygen needs.
The provided label excerpt does not mention imaging or oxygen assessment for pneumonitis.
Infliximab is commonly used for steroid-refractory immune colitis associated with Yervoy when appropriate.
No infliximab specificity appears in the provided label excerpt.
Hydration and correction of electrolyte issues may be important in Yervoy-associated colitis/diarrhea management.
Not stated in the provided label excerpt.
New or worsening rash after Yervoy that involves blistering, widespread involvement, or mucous membrane involvement requires urgent assessment.
Not stated in the provided label excerpt.
Patients should report symptoms rapidly because serious immune toxicities from Yervoy can progress quickly.
The provided label excerpt emphasizes early identification/management but does not state 'progress quickly' or 'report rapidly' in this way.
Patients are instructed to contact their care team right away for warning signs such as frequent or severe diarrhea, blood in stool, and severe abdominal pain.
Specific patient-warning wording for these symptoms is not present in the provided label excerpt.
Patients are instructed to contact their care team right away for warning signs such as shortness of breath or new or worsening cough.
Specific patient-warning wording for these symptoms is not present in the provided label excerpt.
Patients are instructed to contact their care team right away for warning signs such as yellowing of skin or eyes, dark urine, and severe fatigue with abnormal labs.
Specific patient-warning wording for these symptoms is not present in the provided label excerpt.
Patients are instructed to contact their care team right away for warning signs such as severe rash, blistering, or sores in the mouth.
Specific patient-warning wording for these symptoms is not present in the provided label excerpt.
Patients are instructed to contact their care team right away for warning signs such as reduced urine output or swelling, which may indicate kidney involvement.
Specific patient-warning wording for these symptoms is not present in the provided label excerpt.
Additional immunosuppressants beyond steroids for severe or steroid-nonresponsive Yervoy immune-related toxicities are chosen to match the organ system and risk profile.
No such selection rationale is described in the provided label excerpt.
Early recognition of Yervoy immune-related inflammation generally improves the odds of controlling inflammation before it becomes life-threatening.
Label says early identification/management are essential, but the provided excerpt does not state this 'odds of controlling before life-threatening' phrasing.
Continuing Yervoy during a serious immune reaction can increase risk.
Provided label excerpt does not explicitly state this risk statement.
Contradictions
Important Omissions
Boxed warning status (if applicable) and label-supported contraindications were not assessed because they were not included in the provided evidence sections.
Importance:
Low
Label-specific baseline monitoring and before-dose lab monitoring details (liver enzymes, creatinine, ACTH, thyroid function) were not fully reflected in the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most management fundamentals are label-aligned (severity-based withholding/discontinuation, systemic corticosteroids, tapering, consider additional immunosuppressants, and infectious workup for steroid-refractory colitis). However, several over-specific or unsupported operational claims (e.g., infliximab use, pneumonitis imaging/oxygen assessment, detailed patient contact instructions, and 'treat as immune-mediated until proven otherwise') could mislead clinical practice or patient counseling if treated as label-accurate.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple extracted claims are unsupported or framed as typical/operationally specific beyond what the provided label excerpt states (notably infliximab specificity, pneumonitis evaluation details, and detailed patient-warning wording).
Suggested Improvement
Restrict claims to label text: use general statements supported by 5.1/2.3 (early identification/management; monitor for signs/symptoms; institute prompt medical management; withhold/discontinue by severity/grade; systemic corticosteroids with taper after improvement; consider other systemic immunosuppressants if not controlled; infectious workup for corticosteroid-refractory colitis). Remove or rephrase unsupported specifics (e.g., infliximab, imaging/oxygen, and detailed patient counseling triggers) unless supported by additional label sections not provided here.